Objective: We examined the feasibility of regimen selection for first-line irinotecan, 5-fluorouracil and leucovorin or oxaliplatin, 5-fluorouracil and leucovorin in Japanese patients with advanced colorectal cancer based on UDP-glucuronosyltransferase 1A1 genotype as well as physical status of patients related to diarrhea. Methods: As first-line irinotecan, 5-fluorouracil and leucovorin is a little bit superior to oxaliplatin, 5-fluorouracil and leucovorin with respect to efficacy and toxicity, patients without risk factors of irinotecan-induced toxicity were first assigned to irinotecan, 5-fluorouracil and leucovorin. Patients with UDP-glucuronosyltransferase 1A1*28/*28, *6/*6, *28/*6 or *28/*27 and those with ascites, peritoneal dissemination or diarrhea first received oxaliplatin, 5-fluorouracil and leucovorin to avoid the irinotecan-induced neutropenia and diarrhea, respectively. We retrospectively evaluated the feasibility of this strategy by assessing toxicity and total progression-free survival in first-and subsequent second-line therapies in all patients studied. Results: In the first-line irinotecan, 5-fluorouracil and leucovorin (n ¼ 61), Grade 4 neutropenia, febrile neutropenia and Grade 3 diarrhea occurred in 8.2, 3.3 and 3.3% of patients, respectively. In the first-line oxaliplatin, 5-fluorouracil and leucovorin (n ¼ 26), Grade 4 neutropenia, febrile neutropenia, Grade 3 thrombocytopenia and Grade 3 neuropathy were observed in 11.5, 3.8, 3.8 and 7.7% of patients, respectively. In the second-line oxaliplatin, 5-fluorouracil and leucovorin (n ¼ 38), Grade 3 diarrhea occurred in 2.6% of patients. In the second-line irinotecan monotherapy (n ¼ 11), Grade 4 or febrile neutropenia occurred in 18% of patients and Grade 3 diarrhea in 9.1% of patients. In second-line S-1 (n ¼ 9), Grade 3 anemia occurred in 2 patients. Median total progression-free survival in all 87 patients was 11.5 months. Conclusions: Present regimen selection strategy would be feasible, since it causes less toxicity and similar efficacy comparing to previous studies. Determination of appropriate reduced dose in the second-line irinotecan monotherapy or other standard second-line therapy for patients with high-risk to irinotecan-induced toxicity might make this strategy more effective.
INTRODUCTION
Irinotecan is a camptothecin derivative that exerts cytotoxic effects by inhibiting topoisomerase I. This drug has been approved for the treatment of a wide variety of solid tumors, including colorectal cancer. However, patients and oncologists are deeply concerned about the dose-limiting toxic effects of irinotecan, such as myelosuppression and delayed-type diarrhea (1 -3) . Combined therapy with irinotecan, 5-fluorouracil (5-FU) and leucovorin (LV) (FOLFIRI) has been proven to be highly effective for the first-line treatment of patients with advanced colorectal cancer (4) . The combination of oxaliplatin, 5-FU and LV (FOLFOX) is also a standard first-line regimen for advanced colorectal cancer (5) . These regimens provide similar survival benefits, but have different toxicological profiles, depending mainly on the use of irinotecan or oxaliplatin. Furthermore, FOLFIRI followed by FOLFOX is associated with slightly, but not significantly longer survival than FOLFOX followed by FOLFIRI. In addition, the response rate of FOLFOX is superior to that of FOLFIRI when these regimens are used as the second-line therapy (5) . Taking these lines of evidence into consideration, FOLFIRI is superior to FOLFOX as firstline treatment for patients with advanced colorectal cancer, if the patients do not have backgrounds, which are related to irinotecan-induced severe neutropenia or diarrhea.
Previously, physicians predicted the irinotecan-induced adverse events in FOLFIRI according to only physical conditions of patients with advanced colorectal cancer. Physicians tended not to use FOLFIRI as the first-line therapy for patients with ascites, peritoneal dissemination or diarrhea to avoid severe diarrhea induced by irinotecan. On the other hand, there have been no predictive markers of irinotecan-related severe neutropenia.
Several studies have linked UDP-glucuronosyltransferase (UGT) 1A1*28 genotype to irinotecan-related neutropenia. Patients homozygous for UGT1A1*28 have a significantly higher risk of severe neutropenia due to irinotecan than those who do not possess this genotype (6, 7) , because UGT1A1*28 decreases UGT1A1 protein expression and reduces glucuronidation capacity for SN-38. In Asians, a specific mutation, UGT1A1*6 (8), has been proven to reduce the catalytic activity of UGT1A1 (9, 10) . The UGT1A1*28/ *28, *6/*6 and *6/*28 genotypes have been shown to be related not only to a lower ratio of the area under the plasma concentration -time curve of SN-38G to that of SN-38, but also to severe neutropenia in Asian populations (11 -13) . Compound heterozygotes of UGT1A1*28 and UGT1A1*27 seen in Japanese were also suggested to be related to severe neutropenia of irinotecan (6) . Thus, the UGT1A1 genotyping was established as predictive marker for irinotecan-induced severe neutropenia and was approved not only by the Food and Drug Administration in the USA but also by the Ministry of Health, Labour and Welfare of Japan.
Given that, we established a strategy for the regimen selection of FOLFIRI as the first-line therapy for patients with advanced colorectal cancer, aiming to avoid the irinotecan-induced severe toxicities that are related to the reduced dose intensity of irinotecan (Fig. 1) . We considered the UGT1A1 genetic testing in addition to the clinical physical status of patients to select FOLFIRI or FOLFOX regimen. Patients with UGT1A1*28/*28, *6/*6, *28/*6 or *28/*27 first received FOLFOX to avoid the irinotecan-induced severe neutropenia. Patients who had the risk factor of irinotecan-induced severe diarrhea including ascites, peritoneal dissemination and diarrhea also first received FOLFOX, even though they possessed UGT1A1*1/ *1, *1/*6 or *1/*28 genotypes. Patients with UGT1A1*1/ *1, *1/*28 or *1/*6 and without the risk factor of irinotecan-induced severe diarrhea received first-line FOLFIRI.
To evaluate the feasibility of this regimen selection strategy for first-line FOLFIRI and FOLFOX, we retrospectively assessed toxicity and efficacy in first-line and subsequent second-line chemotherapies in all patients studied.
PATIENTS AND METHODS

PATIENTS
All patients with a histologically confirmed diagnosis of advanced colorectal cancer who had an Eastern Cooperative Oncology Group performance status of 0 -2, adequate bone marrow, liver and renal functions and no history of chemotherapy for advanced disease were eligible. Patients with diarrhea of four times a day or more were excluded. Any previous adjuvant chemotherapy must have been completed at least 6 months before treatment. All patients signed 
SECOND-LINE TREATMENTS
FOLFOX was given by the same method as the first-line treatment. Irinotecan monotherapy regimen comprised a 1.5-h intravenous infusion of irinotecan (150 mg/m 2 ), repeated every 2 weeks. S-1 was given per oral twice daily for 28 consecutive days, followed by 2 weeks of rest. The dose of S-1 was fixed based on the patients' body surface area (BSA) according to the manufacturer's package insert as distributed in Japan. The dose was 80 mg/day for patients with a BSA of ,1.25 m 2 , 100 mg/day for those with a BSA of 1.25 -1.5 m 2 and 120 mg/day for those with a BSA of .1.5 m 2 .
EVALUATION OF EFFICACY AND TOXICITY
Toxicity was assessed according to the National Cancer Institute common terminology criteria for adverse events, version 3.0 (http://ctep.cancer.gov/reporting/ctc_v30.html). Tumor response was assessed according to the Response Evaluation Criteria in Solid Tumors (http://www.recist.com/ index.html) for at least 2 months by computed tomography imaging or ultrasonography. Efficacy was evaluated on the basis of the overall response rate and progression-free survival (PFS). PFS was defined as the date of starting treatment with FOLFIRI, FOLFOX or second-line chemotherapies to the date of disease progression as defined by the RECIST criteria or the date of death from any cause. The same imaging method was used for baseline tumor measurements and tumor reassessments. Total PFS was defined as the summation of PFSs in first-and second-line chemotherapies observed in respective patients. When patients did not receive second-line chemotherapy, the total PFS was equal to the PFS in first-line chemotherapy.
UGT1A1 GENOTYPING Genomic DNA was extracted from 200 ml of peripheral blood, which had been stored at 2808C until analysis, with the use of a QIAamp Blood Kit (QIAGEN GmbH, Hilden, Germany). Two polymorphisms [G71R (*6) and P229Q (*27)] were analyzed by the polymerase chain reactionrestriction fragment length polymorphism method, as described elsewhere (14) . The TATA box polymorphism (*28) was determined by the direct sequencing method, as described by Fujita et al. (14) .
STATISTICAL ANALYSIS
Total PFS was calculated by the Kaplan -Meier method. The analysis was conducted using JMP version 6 software (SAS Institute, Inc., Cary, NC).
ASSESSMENT OF FEASIBILITY OF THE PRESENT REGIMEN SELECTION
The feasibility of the selection strategy for first-line FOLFIRI or FOLFOX was assessed by toxicity and efficacy in all patients: (1) Frequencies of typical toxicity(ies) for first-line FOLFIRI and FOLFOX, and the second-line chemotherapies were equal to or less than those observed in representative previous studies; (2) Total PFS in first-and subsequent second-line chemotherapies observed in all patients studied was almost equal to that in representative previous studies.
RESULTS
PATIENT CHARACTERISTICS
A total of 112 patients with advanced colorectal cancer received first-line chemotherapy from June 2003 through April 2008. Chemotherapeutic regimens given to all of the patients are shown in Table 1 . First-line FOLFIRI was given to 61 patients and FOLFOX to 26. These 87 patients were studied. Patient characteristics are shown in Table 2 . Six patients received first-line FOLFOX based on UGT1A1 genotypes and 20 patients received FOLFOX according to their physical conditions to avoid irinotecan-induced toxicity.
TOXICITY IN FIRST-LINE TREATMENTS
The main adverse events associated with first-line FOLFIRI or FOLFOX are presented in Table 3 . In FOLFIRI, Grade 4 neutropenia occurred in 5 (8.2%) patients. Febrile neutropenia and Grade 3 diarrhea were seen in 2 (3.3%) patients. In FOLFOX, Grade 4 neutropenia occurred in 3 (11.5%) patients. Febrile neutropenia and Grade 3 thrombocytopenia were observed in one patient (3.8%). Grade 3 neuropathy occurred in 2 (7.7%) patients. However, no other Grade 3 or 4 non-hematological adverse events occurred in FOLFOX.
No patient who harbored UGT1A1*6/*6, *28/*6 or *28/*27 receiving FOLFOX had Grade 4 neutropenia or other toxic effects of Grade 3 or higher. The discontinuation of FOLFIRI or FOLFOX due to toxicity were 3 (4.9%) and 5 (19%) patients, respectively. There were no treatment-related deaths in both groups.
EFFICACY IN FIRST-LINE CHEMOTHERAPIES
The efficacy of first-line FOLFIRI or FOLFOX was evaluated on the basis of the overall response rate and PFS (Table 4) . The overall response rates were 43% in FOLFIRI and 46% in FOLFOX (Table 3) . Median PFS was 7.5 months in FOLFIRI and was 8.7 months in FOLFOX. The median number of FOLFIRI and FOLFOX treatments were 7.0 (range of 1 -38) and 6.5 (range of 1 -18), respectively.
SECOND-LINE CHEMOTHERAPIES
Among the patients who received first-line FOLFIRI, 38 patients (62%) received second-line FOLFOX and 4 (7%) S-1. The remaining 19 (31%) did not receive any second-line chemotherapies (10 others including surgery or radiotherapy and 9 best supportive care). In second-line FOLFOX, no Grade 4 or febrile neutropenia was observed. Grade 3 In patients treated with first-line FOLFOX, 11 patients (42%) received second-line irinotecan monotherapy, 5 (19%) S-1 and 10 (38%) best supportive care. In second-line irinotecan monotherapy group, Grade 4 or febrile neutropenia was observed in respective 2 patients (18%). Grade 3 anemia and Grade 3 thrombocytopenia occurred in 2 (18%) and 1 patient (9.1%), respectively. Grade 3 diarrhea occurred in 1 patient (9.1%). The overall response rate and median PFS in the second-line irinotecan monotherapy were 0% and 2.0 months, respectively. In the second-line S-1, Grade 3 anemia occurred in one patient. No other Grade 3 or 4 adverse events were observed. The overall response rate and median PFS in second-line S-1 were 0% and 1.5 months, respectively.
Among six patients with UGT1A1*6/*6, *28/*6 or *28/ *27 who received first-line FOLFOX, three received secondline irinotecan monotherapy, one was given S-1 and others received best supportive care. Irinotecan therapy was started with the standard dose of 150 mg/m 2 in Japan, because there has been no information regarding the optimal reduced dose of irinotecan for patients possessing these UGT1A1 genotypes. Among three patients given second-line irinotecan monotherapy, two patients experienced respective Grade 3 or 4 neutropenia and one patient Grade 3 diarrhea. The irinotecan doses in these patients for the next courses were reduced by the physicians in charge.
TOTAL PFS IN FIRST-AND SECOND-LINE THERAPIES IN ALL PATIENTS EXAMINED
The median total PFS in all 87 patients studied was 11.5 months (Fig. 2) .
DISCUSSION
This is the first study to select the first-line FOLFIRI or FOLFOX regimen by considering UGT1A1 genetic testing in addition to physical conditions in patients with advanced colorectal cancer. The feasibility of this strategy was evaluated as follows:
1. The toxicities observed during the all first-and secondline chemotherapies were compared with those observed in representative studies.
In patients treated with first-line FOLFIRI, the frequency of Grade 4 neutropenia was slightly lower than that previously reported (9%) (4, 5, 15) . The frequencies of febrile neutropenia and Grade 3 diarrhea were lower than those reported previously (febrile neutropenia, 7% and Grade 3 -4 diarrhea, 14%) (4, 5, 15) . The patient selection for FOLFIRI adopted in the present strategy appears to be effective to reduce the irinotecan-induced toxicities. In the first-line FOLFOX, the frequencies of Grade 4 neutropenia, Grade 3 thrombocytopenia and Grade 3 neuropathy were lower than those reported previously (Grade 4 neutropenia, 13%; Grade 3 thrombocytopenia, 5% and Grade 3 neuropathy, 34%) (4, 5, 15) . Patients who were assigned to FOLFOX because of ascites, peritoneal dissemination and diarrhea did not suffer from Grade 3 or higher gastrointestinal adverse events such as nausea, vomiting and diarrhea, which were relatively often observed in FOLFIRI. Furthermore, no patient who harbored UGT1A1*6/*6, *28/*6 or *28/*27 receiving Table 4 . Response rate and progression-free survival in patients treated with first-line FOLFIRI or FOLFOX FOLFOX had Grade 4 neutropenia or other toxic effects of Grade 3 or higher.
In second-line FOLFOX, the frequencies of Grade 3 or 4 neutropenia, Grade 3 thrombocytopenia and Grade 3 neuropathy were lower than those reported previously (Grade 4 neutropenia, 17%; Grade 3 thrombocytopenia, 1% and Grade 3 neuropathy, 20%) (5). The frequency of toxicities seen in the second-line irinotecan monotherapy was compared with that in the second-line FOLFIRI (5), since (i) there have been few studies of second-line irinotecan monotherapy with large number of patients and (ii) we can evaluate the toxicity more severely in second-line irinotecan monotherapy, because FOLFIRI is stronger than irinotecan monotherapy in terms of toxicity. The frequencies of Grade 3 or 4 neutropenia and febrile neutropenia seen in second-line irinotecan monotherapy were higher than those previously reported (Grade 3 or 4 neutropenia, 21% and febrile neutropenia, 1%) (5), while the frequency of Grade 3 diarrhea was similar to that reported previously (8%) (5). Because patients who had the risk factor for irinotecan-induced severe toxicity received second-line irinotecan monotherapy, frequencies of severe neutropenia and febrile neutropenia were higher than that previously reported. In second-line S-1, the frequency of Grade 3 anemia was similar to that reported in previous study (16) . The frequencies of non-hematological toxicities such as nausea, diarrhea and mucositis were lower than those reported previously (16) .
Collectively, the present regimen selection strategy appears to be feasible in terms of toxicities, except for the patients with risk for irinotecan-induced toxicity who received the second-line irinotecan monotherapy. Appropriate reduced dose should be determined and other chemotherapies without irinotecan should be developed for these patients.
2. The median total PFS in all 87 patients evaluated was 11.5 months (Fig. 2) . We compared this clinical outcome during first-and second-line treatments with duration of disease control (DDC) used in OPTIMOX studies, which collected the data until second-line therapy (17, 18) , since the definition of DDC is almost equal to that of our total PFS. In OPTIMOX studies, DDC was defined as PFS in first-line FOLFOX and maintenance with simplified 5-FU and LV regimen plus PFS of FOLFOX reintroduction (17, 18) . The median total PFS of 11.5 months in our study was almost similar to that reported in OPTIMOX studies (10.6 -13.1 months) (17, 18) .
Taking these considerations into account, the regimen selection of the first-line FOLFIRI or FOLFOX therapy based on the UGT1A1 genotyping in addition to patient physical conditions that are related to irinotecan-induced toxicity might be feasible, since it causes less toxicity and similar efficacy comparing to previous studies. Determination of appropriate reduced dose in second-line irinotecan monotherapy or other standard second-line therapy for patients with high risk to irinotecan-induced toxicity might make this strategy more effective.
Previous studies of first-line FOLFIRI therapy in patients with advanced colorectal cancer have reported the response rate of 31 -56% and PFS of 8.5 months (4, 5, 15) . First-line FOLFOX therapy showed the similar efficacy as FOLFIRI (response rate, 34 -54% and PFS, 8.0 months) (5, 15, 19) . In our study, the response rate and PFS in patients assigned to FOLFIRI or FOLFOX were comparable to those reported previously. It should be noted that the response rate and PFS [50% and 8.6 months (range of 2.5 -15.2)] seen in patients who received FOLFOX because of harboring UGT1A1*6/*6, *28/ *6 or *28/*27 genotype were not statistically significantly different from those observed in patients assigned to FOLFIRI.
To further confirm the present results, the prospective study involving larger numbers of patients should be planned to confirm our data, even though many patients are now treated with FOLFIRI or FOLFOX combined with monoclonal antibodies such as bevacizumab or cetuximab as the first-line therapy for advanced colorectal cancer in Japan (20) (21) (22) (23) .
At present, there has been no evidence whether or not the present strategy is applicable when FOLFIRI or FOLFOX are used in combination with bevacizumab or cetuximab. Further studies are necessary to confirm this point.
If the optimal reduced dose(s) of irinotecan can be determined for patients who have a high risk of irinotecaninduced neutropenia because of UGT1A1*28/*28, *6/*6, *28/*6 or *28/*27 genotype, UGT1A1 genotyping should become essential not only for regimen selection but also for dose decision-making.
In summary, our results demonstrate that the selection of first-line FOLFIRI or FOLFOX in patients with advanced colorectal cancer based on UGT1A1 genotyping in addition to patient physical condition would be feasible, since it causes less toxicity and similar efficacy comparing to previous studies. Determination of appropriate reduced dose in second-line irinotecan monotherapy or other standard second-line therapy for patients with high risk to irinotecan-induced toxicity might make this strategy more effective. Severe irinotecan-induced neutropenia in first-line FOLFIRI was avoided in patients with UGT1A1*28/*28, *6/*6, *28/*6 or *28/*27 by assigning these patients to firstline FOLFOX. This strategy of regimen selection for firstline FOLFIRI and FOLFOX might be feasible. Regimen selection of FOLFIRI or FOLFOX
